

# Jeffrey S Stonebraker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3763129/publications.pdf>

Version: 2024-02-01

33  
papers

1,002  
citations

623734

14  
h-index

501196

28  
g-index

33  
all docs

33  
docs citations

33  
times ranked

923  
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. <i>Annals of Internal Medicine</i> , 2019, 171, 540.	3.9	228
2	A study of variations in the reported haemophilia A prevalence around the world. <i>Haemophilia</i> , 2010, 16, 20-32.	2.1	224
3	A study of variations in the reported haemophilia B prevalence around the world. <i>Haemophilia</i> , 2012, 18, e91-4.	2.1	93
4	A study of reported factor VIII use around the world. <i>Haemophilia</i> , 2010, 16, 33-46.	2.1	75
5	The World Federation of Hemophilia Annual Global Survey 1999â€”2018. <i>Haemophilia</i> , 2020, 26, 591-600.	2.1	50
6	Modeling Primary Immunodeficiency Disease Epidemiology and Its Treatment to Estimate Latent Therapeutic Demand for Immunoglobulin. <i>Journal of Clinical Immunology</i> , 2014, 34, 233-244.	3.8	38
7	How Bayer Makes Decisions to Develop New Drugs. <i>Interfaces</i> , 2002, 32, 77-90.	1.5	36
8	The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. <i>Pilot and Feasibility Studies</i> , 2018, 4, 58.	1.2	34
9	Impact factor as a metric to assess journals where OM research is published. <i>Journal of Operations Management</i> , 2012, 30, 24-43.	5.2	24
10	A study of reported factor IX use around the world. <i>Haemophilia</i> , 2011, 17, 446-455.	2.1	23
11	A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community. <i>Haemophilia</i> , 2003, 9, 245-250.	2.1	20
12	Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand. <i>Haemophilia</i> , 2004, 10, 18-26.	2.1	19
13	Nonâ€”severe haemophilia: Is it benign? â€” Insights from the PROBE study. <i>Haemophilia</i> , 2021, 27, 17-24.	2.1	16
14	Formulating and solving sequential decision analysis models with continuous variables. <i>IEEE Transactions on Engineering Management</i> , 1997, 44, 43-53.	3.5	15
15	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. <i>BMJ Open</i> , 2018, 8, e021900.	1.9	15
16	Testâ€”retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. <i>Haemophilia</i> , 2019, 25, 75-83.	2.1	14
17	OR Practiceâ€”Modeling Potential Demand for Supply-Constrained Drugs: A New Hemophilia Drug at Bayer Biological Products. <i>Operations Research</i> , 2009, 57, 19-31.	1.9	13
18	Exploring regional variations in the crossâ€”cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. <i>Haemophilia</i> , 2019, 25, 365-372.	2.1	11

#	ARTICLE	IF	CITATIONS
19	New York Power Authority Uses Decision Analysis to Schedule Refueling of Its Indian Point 3 Nuclear Power Plant. <i>Interfaces</i> , 2001, 31, 121-135.	1.5	10
20	NC State's Supply Chain Resource Cooperative Educates in the Real World. <i>Interfaces</i> , 2011, 41, 548-563.	1.5	10
21	Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. <i>Haemophilia</i> , 2017, 23, e1-e7.	2.1	10
22	Latent therapeutic demand model for the immunoglobulin replacement therapy of primary immune deficiency disorders in the <scp>USA</scp>. <i>Vox Sanguinis</i> , 2018, 113, 430-440.	1.5	7
23	Product-Generation Transition Decision Making for Bayer's Hemophilia Drugs: Global Capacity Expansion Under Uncertainty with Supply-Demand Imbalances. <i>Operations Research</i> , 2013, 61, 1119-1133.	1.9	4
24	Practice Summaries: American Airlines Uses Should-Cost Modeling to Assess the Uncertainty of Bids for Its Full-Truckload Shipment Routes. <i>Interfaces</i> , 2011, 41, 194-196.	1.5	3
25	Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time. <i>Haemophilia</i> , 2021, 27, e596-e608.	2.1	3
26	Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres. <i>Haemophilia</i> , 2021, 27, e22-e29.	2.1	2
27	Evaluation of the sexual health in people living with hemophilia. <i>Haemophilia</i> , 2021, 27, 993-1001.	2.1	2
28	Empirically Investigating the Portfolio Management Process: Findings from a Large Pharmaceutical Company. <i>Profiles in Operations Research</i> , 2011, , 131-148.	0.4	2
29	Balancing Environmental and Operational Objectives in Nuclear Refueling Strategies. , 0, , 564-581.		1
30	Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE). <i>Blood</i> , 2016, 128, 5964-5964.	1.4	0
31	Caseâ€”Bayer New Drug Development Decision Making. <i>INFORMS Transactions on Education</i> , 0, , .	0.5	0
32	Case Articleâ€”Bayer New Drug Development Decision Making. <i>INFORMS Transactions on Education</i> , 0, , .	0.5	0
33	Risk analysis, practice, and considerations in capital budgeting: Evidence from the field for the bio-based industry. <i>BioResources</i> , 2020, 16, 19-45.	1.0	0